<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 09, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05621499</url>
  </required_header>
  <id_info>
    <org_study_id>C20221044</org_study_id>
    <nct_id>NCT05621499</nct_id>
  </id_info>
  <brief_title>HAIC or Lenvatinib Combined With Sintilimab for High Recurrence Risk Resectable Solitary Hepatocellular Carcinoma</brief_title>
  <official_title>The Safety and Efficacy of HAIC or Lenvatinib Combined With Sintilimab as a Neoadjuvant Therapy for High Recurrence Risk Resectable Stage IB Solitary Hepatocellular Carcinoma: a Prospective, Randomized, Two Cohort, Exploratory Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tianjin Medical University Cancer Institute and Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Tianjin Medical University Cancer Institute and Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the safety and efficacy of HAIC or Lenvatinib combined with Sintilimab as a&#xD;
      neoadjuvant therapy for high recurrence risk resectable stage IB solitary hepatocellular&#xD;
      carcinoma&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">November 2022</start_date>
  <completion_date type="Anticipated">November 2025</completion_date>
  <primary_completion_date type="Anticipated">November 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>1-year DFS rate</measure>
    <time_frame>up to 1 years</time_frame>
    <description>To evaluate the 1-year disease free survival rate of neoadjuvant treatment with HAIC or Lenvatinib combined with Sintilimab for of high recurrence risk resectable stage IB solitary hepatocellular carcinoma</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of microvascular invasion</measure>
    <time_frame>Up to 3 years</time_frame>
    <description>Defined as proportion of patients with microvascular invasion</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pathological complete response rate (pCR)</measure>
    <time_frame>up to 1 years</time_frame>
    <description>Defined as proportion of patients who have a best response of pCR</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective response rate</measure>
    <time_frame>Up to 1 years</time_frame>
    <description>Defined as proportion of patients who have a best response of CR or PR</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>2-year DFS rate</measure>
    <time_frame>Up to 3 years</time_frame>
    <description>To evaluate the 2-year disease free survival rate of neoadjuvant treatment with HAIC or Lenvatinib combined with Sintilimab for of high recurrence risk resectable stage IB solitary hepatocellular carcinoma</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>2-year OS rate</measure>
    <time_frame>Up to 3 years</time_frame>
    <description>To evaluate the 2-year overall survival rate of neoadjuvant treatment with HAIC or Lenvatinib combined with Sintilimab for of high recurrence risk resectable stage IB solitary hepatocellular carcinoma</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse Events (AEs)</measure>
    <time_frame>Up to 3 years</time_frame>
    <description>Defined as the proportion of patients with AE, treatment-related AE (TRAE), immune-related AE (irAE), serious adverse event (SAE), assessed by NCI CTCAE v5.0 and complications of surgery</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Hepatocellular Carcinoma</condition>
  <arm_group>
    <arm_group_label>experimental group1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>HAIC</description>
  </arm_group>
  <arm_group>
    <arm_group_label>experimental group 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Lenvatinib+Sintilimab</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HAIC</intervention_name>
    <description>Oxaliplatin 85 mg/m2, LV 400 mg/ m2, 5-FU 400 mg/m2 bolus and then 2400 mg/m2 as 46h continuous infusion，Q3W，a total of 2 cycles</description>
    <arm_group_label>experimental group1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sintilimab</intervention_name>
    <description>200mg，iv，d1，q3w，a total of 3 cycles</description>
    <arm_group_label>experimental group 2</arm_group_label>
    <other_name>IBI308</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lenvatinib</intervention_name>
    <description>12 or 8mg/kg，po，qd，a total of 3 cycles</description>
    <arm_group_label>experimental group 2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Volunteer to join the study and signed the informed consent form&#xD;
&#xD;
          -  Aged 18-75, male or female&#xD;
&#xD;
          -  ECOG PS score 0-1&#xD;
&#xD;
          -  Child Pugh liver function Grade A&#xD;
&#xD;
          -  Histopathology confirmed primary hepatocellular carcinoma (HCC) and the lesion met the&#xD;
             indications for surgical resection in the Diagnostic and Therapeutic Norms for Primary&#xD;
             Liver Cancer (2022)&#xD;
&#xD;
          -  According to the investigator's assessment, there are the following high recurrence&#xD;
             risk factors, Stage Ⅰ b: solitary tumor, with the largest diameter &gt; 5cm&#xD;
&#xD;
          -  At least one measurable lesion according to RECIST 1.1 (measurable lesion CT/MRI scan&#xD;
             length diameter ≥ 10mm or lymph node lesion CT/MRI scan short diameter ≥ 15mm, and&#xD;
             measurable lesion has not received radiotherapy, cryotherapy and other local&#xD;
             treatments)&#xD;
&#xD;
          -  Expected life ≥ 6 months&#xD;
&#xD;
          -  Functions of important organs shall meet the following requirements (excluding the use&#xD;
             of any blood component and cell growth factor within 14 days) Neutrophils ≥&#xD;
             1500/mm3Platelet count ≥ 60,000/mm3Hemoglobin ≥ 5.6 mmol/L (9 g/dL); Serum creatinine&#xD;
             (SCR) ≤ 1.5 times the upper limit of normal value (ULN) or creatinine clearance ≥ 50&#xD;
             ml/min (Cockcroft Gault formula); Total bilirubin (TBIL) ≤ 1.5 times the upper limit&#xD;
             of normal value (ULN); The level of AST or ALT ≤ 2.5 times the upper limit of normal&#xD;
             value (ULN); Urine protein&lt;2+; If urinary protein ≥ 2+, the 24-hour urine protein&#xD;
             quantitative display must be ≤ 1g&#xD;
&#xD;
          -  Normal coagulation function, no active bleeding and thrombosis disease&#xD;
&#xD;
               1. International normalized ratio INR ≤ 1.5 × ULN；&#xD;
&#xD;
               2. Partial thromboplastin time APTT ≤ 1.5 × ULN；&#xD;
&#xD;
               3. Prothrombin time PT ≤ 1.5ULN;&#xD;
&#xD;
          -  Women of childbearing age should agree to use contraceptive measures (such as&#xD;
             intrauterine devices, contraceptives or condoms) during the medication period and&#xD;
             within 6 months after the end of medication; If the serum or urine pregnancy test was&#xD;
             negative within 7 days before the study included, and the patient must be a non&#xD;
             lactating patient, the male should agree to use contraception during the study period&#xD;
             and within 6 months after the end of the study period&#xD;
&#xD;
          -  The subjects had good compliance and cooperated with follow-up.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Previously received radiotherapy, chemotherapy, concurrent radiotherapy and&#xD;
             chemotherapy or other targeted therapies&#xD;
&#xD;
          -  Known hepatobiliary cell carcinoma, sarcomatoid HCC, mixed cell carcinoma and&#xD;
             fibrolamellar cell carcinoma; Have other active malignant tumors except HCC within 5&#xD;
             years or at the same time&#xD;
&#xD;
          -  Patients with hypertension who cannot be well controlled after antihypertensive drug&#xD;
             treatment (systolic blood pressure ≥ 140 mmHg or diastolic blood pressure ≥ 90 mmHg);&#xD;
             Previous hypertension crisis or hypertensive encephalopathy&#xD;
&#xD;
          -  Patients had other malignant tumors in the past or at the same time (except cured skin&#xD;
             basal cell carcinoma and cervical carcinoma in situ);&#xD;
&#xD;
          -  Patients who had been treated with Sintilimab or other PD-1/PD-L1 inhibitors in the&#xD;
             past could not be included; Known hypersensitivity to macromolecular protein&#xD;
             preparations or any excipients of Sintilimab or lenvatinib&#xD;
&#xD;
          -  Patients have any active autoimmune diseases or have a history of autoimmune diseases&#xD;
             (Including but not limited to: autoimmune hepatitis, interstitial pneumonia, uveitis,&#xD;
             enteritis, hepatitis, hypophysitis, vasculitis, nephritis, hyperthyroidism,&#xD;
             hypothyroidism; Patients with vitiligo or asthma in childhood has completely&#xD;
             alleviated, without any intervention after adulthood can be included; Patients with&#xD;
             asthma requiring medical intervention of bronchodilators cannot be included)&#xD;
&#xD;
          -  Patients who are using immunosuppressive agents, or systemic or absorbable local&#xD;
             hormone to achieve immunosuppressive purpose (Dose&gt;10mg/day prednisone or other&#xD;
             equivalent therapeutic hormones) and continue to use them within 2 weeks before&#xD;
             enrollment&#xD;
&#xD;
          -  Ascites or pleural effusion with clinical symptoms and requiring therapeutic puncture&#xD;
             or drainage&#xD;
&#xD;
          -  There are clinical symptoms or diseases of the heart that are not well controlled,&#xD;
             such as:&#xD;
&#xD;
               1. Heart failure above NYHA level 2&#xD;
&#xD;
               2. Unstable angina pectoris&#xD;
&#xD;
               3. Myocardial infarction occurred within 1 year&#xD;
&#xD;
               4. Clinically significant supraventricular or ventricular arrhythmia requiring&#xD;
                  treatment or intervention&#xD;
&#xD;
          -  Patients having gastrointestinal diseases such as esophageal varices, active gastric&#xD;
             and duodenal ulcers, ulcerative colitis, portal hypertension, or active bleeding from&#xD;
             tumors that have not been removed, or other conditions that may cause gastrointestinal&#xD;
             bleeding and perforation as determined by the investigator at present (within 3&#xD;
             months)&#xD;
&#xD;
          -  Serious bleeding (&gt;30 ml bleeding within 3 months), hemoptysis (&gt;5 ml fresh blood&#xD;
             within 4 weeks) or thromboembolism (including stroke and/or transient ischemic attack)&#xD;
             occurred in the past or present&#xD;
&#xD;
          -  Patients with active infection or fever of unknown origin&gt;38.5℃during the screening&#xD;
             period and before the first administration (according to the judgment of the&#xD;
             investigator, subjects with fever due to tumor can be included)&#xD;
&#xD;
          -  Patients with past or current objective evidence of pulmonary fibrosis history,&#xD;
             interstitial pneumonia, pneumoconiosis, radiation pneumonia, drug-related pneumonia,&#xD;
             and severe impairment of pulmonary function&#xD;
&#xD;
          -  Patients with congenital or acquired immune deficiency, such as HIV infection, or&#xD;
             active hepatitis (transaminase does not meet the inclusion criteria: HBV DNA ≥&#xD;
             10e4/ml; HCV RNA ≥ 10e3/ml); Chronic hepatitis B virus carriers with HBV DNA&lt;2000&#xD;
             IU/ml (&lt;10e4 copies/ml) receive antiviral treatment at the same time during the trial&#xD;
             can be included&#xD;
&#xD;
          -  Live vaccine may be inoculated less than 4 weeks before the study medication or during&#xD;
             the study period&#xD;
&#xD;
          -  Known history of abuse of psychotropic substances, alcohol abuse or drug abuse&#xD;
&#xD;
          -  Conditions should be excluded according to the judgment of the investigator, for&#xD;
             example, according to the judgment of the investigator, the patient has other factors&#xD;
             that may lead to the forced termination of the study, such as other serious diseases&#xD;
             requiring combined treatment, serious laboratory examination abnormalities, and family&#xD;
             or social factors, which may affect the safety of the subject, or the collection of&#xD;
             data and samples.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Yunlong Cui</last_name>
    <phone>18622228633</phone>
    <email>ningyunlong@163.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Tianjin Medical University Cancer Institute &amp; Hospital</name>
      <address>
        <city>Tianjin</city>
        <state>Tianjin</state>
        <zip>300060</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Yunlong Cui</last_name>
      <phone>18622228633</phone>
      <email>ningyunlong@163.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>November 2022</verification_date>
  <study_first_submitted>November 10, 2022</study_first_submitted>
  <study_first_submitted_qc>November 10, 2022</study_first_submitted_qc>
  <study_first_posted type="Actual">November 18, 2022</study_first_posted>
  <last_update_submitted>November 10, 2022</last_update_submitted>
  <last_update_submitted_qc>November 10, 2022</last_update_submitted_qc>
  <last_update_posted type="Actual">November 18, 2022</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
    <mesh_term>Recurrence</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lenvatinib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

